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Abstract 
Purpose: The influence of polymer architecture on cellular uptake and transport across 
Caco-2 cells of novel amphiphilic polyelectrolyte-insulin nanocomplexes was 
investigated.  
Method: Polyallylamine (PAA) (15 kDa) was grafted with palmitoyl chains (Pa) and 
subsequently modified with quaternary ammonium moieties (QPa). These two 
amphiphilic polyelectrolytes (APs) were tagged with rhodamine and their uptake by 
Caco-2 cells or their polyelectrolyte complexes (PECs) with fluorescein isothiocyanate-
insulin (FITC-insulin) uptake were investigated using fluorescence microscopy. The 
integrity of the monolayer was determined by measurement of transepithelial electrical 
resistance (TEER). Insulin transport through Caco-2 monolayers was determined during 
TEER experiments.  
Result: Pa and insulin were co-localised in the cell membranes while QPa complexes 
were found within the cytoplasm. QPa complex uptake was not affected by calcium, 
cytochalasin D or nocodazole.  Uptake was reduced by co-incubation with sodium azide, 
an active transport inhibitor. Both polymers opened tight junctions reversibly where the 
TEER values fell by up to 35 % within 30 minutes incubation with Caco-2 cells. Insulin 
transport through monolayers increased when QPa was used (0.27 ngmL
-1 
of insulin
 
in 
basal compartment) compared to Pa (0.14 ngmL
-1 
of insulin in basal compartment) after 2 
hours.  
Conclusion: These APs have been shown to be taken up by Caco-2 cells and reversibly 
open tight cell junctions. Further work is required to optimise these formulations with a 
view to maximising their potential to facilitate oral delivery of insulin. 
Keywords: amphiphilic polyelectrolytes, Caco-2, transepithelial electrical resistance, 
insulin, quaternary ammonium moiety. 
 
 
1. Introduction 
Daily subcutaneous injections of insulin are required for the treatment of Type 1 diabetes 
mellitus and some individuals with Type 2 diabetes mellitus. Patients find this route of 
delivery undesirable due to the requirement to self-inject and the difficulties involved in 
maintaining glucose control (1-4). Therefore attempts have been made to deliver insulin 
via other routes such as nasal (2) and pulmonary (5). Attempts have also been made to 
deliver insulin orally as this is the most acceptable delivery route for both patients and 
clinicians (6-8). However there are a number of barriers to overcome in oral protein 
delivery. The large molecular weight and hydrophilic nature of proteins mean that they 
cannot diffuse across gastrointestinal tract (GIT) epithelial cells. In addition enzymes 
present in the GIT degrade therapeutic proteins such that very little of the protein is 
available for absorption (9-13). Several different technologies have been used to facilitate 
oral protein absorption and prevent degradation. These include the co-administration of 
enzyme inhibitors and/or penetration enhancers, pro-drug forms of proteins and colloids 
such as polyelectrolyte carrier systems (2, 6-8, 12, 14-17).  
Cationic polyelectrolytes such as chitosan or its derivatives (i.e. trimethylated chitosan 
(TMC)) have been shown to form nano-complexes with proteins and facilitate protein 
transport across gut epithelial cells in vitro via both paracellular and transcellular routes 
(7, 8, 15, 18-22). They promote paracellular transport by interacting with tight junction 
proteins via electrostatic interaction and thereby causing a temporary change in cell 
morphology. This leads to tight junction opening which in turn allows protein passage 
between cells (19, 23-26). These interactions have been shown to be reversible and less 
likely to result in permanent cellular damage compared to traditional permeation 
enhancers, i.e. carbomers and surfactants (27). Transcellular transport is also possible 
using PEC. It is believed that they are taken up by endocytosis/transcytosis although the 
exact mechanisms involved in the uptake have not been fully elucidated (2, 7, 8, 26).  
There are a handful of reports on the use of AP for oral protein delivery (6, 14).  These 
types of systems thus far have been widely explored as hydrophobic drug solubilisers 
mainly for intravenous administration due to their ability to form polymeric micelles in 
aqueous solution (28). Unlike polyelectrolytes modified with hydrophilic moieties such 
as TMC (2), AP consist of both hydrophilic and hydrophobic moieties within the same 
macromolecules. These hydrophobic moieties enable these systems to interact with 
proteins via both electrostatic and hydrophobic interactions (6, 14, 29, 30). These 
additional interactions may reduce the problem of counterion effects in vivo which can 
cause PEC collapse when only electrostatic interactions are present (31).  
To date, there are limited studies on the interaction of these amphiphilic polyelectrolytes-
protein nanocomplexes with the intestinal epithelial cells where the studies mainly 
focused on paracellular transport. Simon et al. (2007) found that AP opened tight cell 
junctions, but did not investigate whether paracellular or transcellular transport occurred 
with their AP (6). Our previous work involved the use of novel amphiphilic 
polyelectrolytes based on 15 kDa PAA to form PECs in Tris buffer. We have previously 
shown that the nano-complexes with the hydrodynamic size of 200 nm were formed 
spontaneously at room temperature upon mixing (29).  These complexes have shown 
varying ability to protect insulin from in vitro enzymatic degradation (29, 30). From 
results from previous studies (29, 30) it was decided to use AP with palmitoyl grafts 
given that they demonstrated the highest complexation efficiency and protection against a 
range of gastro-intestinal enzymes compared to AP with other hydrophobic grafts.  
The success of oral protein delivery systems is dependant mainly on two factors: the 
ability of the systems to protect against enzymatic degradation as well as facilitate the 
transport of protein across the gut epithelial cells. Hence, in this study we have monitored 
the uptake of two APs, Pa grafted PAA and QPa grafted PAA by Caco-2 cells and 
determined the uptake mechanisms of the polymers and their PECs. The ability of these 
polymers to open tight cell junctions and facilitate insulin transport across Caco-2 
monolayers has also been undertaken. 
 
2. Materials and Methods 
 
2.1. Materials 
Poly(allyl amine hydrochloride) (Mw≈15 kDa), palmitic acid-N-hydroxysuccinimide 
ester (98 %), tris(hydroxymethyl) aminomethane (Tris base) (≥99 %), insulin (27 U/mg, 
bovine pancreas), minimum essential media eagle media (EMEM), phosphate buffer 
tablets (PBS), rhodamine Β isothiocyanate (RBITC), FITC-insulin, gluteraldehyde (grade 
I, 25 % in water), Hank’s balanced salt solution with sodium bicarbonate, magnesium and 
calcium (HBSS) and sodium azide were all purchased from Sigma Aldrich, UK. Methyl 
iodide and all solvents were purchased from Fisher Scientific Chemicals, UK and were of 
HPLC grade. All other reagents used were of analytical grade. Cell culture reagents such 
as L-Glutamine (200 mM), Trypsin-EDTA (0.05 %), trypan blue, DAPI, nocodazole, 
cytochalasin D, non-essential amino acids, Penicillin/Streptomycin (+ 10000 UmL
-1
/+ 
10000 μLmL-1) were obtained from Invitrogen, Scotland and foetal bovine serum 
(activated) (South American) from Biosera, UK.  
 
2.2. Rhodamine-labeling of amphiphilic polymers 
The amphiphilic polymer, PAA grafted with 2.5% mole modification of palmitoyl 
pendant groups (Pa2.5) was produced as previously described (29). RBITC grafting was 
carried out using a method adapted from Lin and coworkers (2008) (32). Briefly, a 95 mL 
0.05 % (w/v) solution of Pa2.5 in double distilled water was prepared. Five mL of a 1 
mgmL
-1
 solution of RBITC in DMSO was added to the polymer solution drop wise over 
10 mins with gentle stirring on a magnetic stirrer. The solution was stirred for one hour at 
room temperature before being placed in a dialysis membrane (12-14 kDa cutoff; 
Medicell, UK) and dialysed against 5 L of double distilled water. The water was changed 
six times every 24 h and the dialysis was carried out over 48 h to ensure all non-bound 
RBITC was removed. The contents of the dialysis bag were then lyophilized over 72 h to 
produce a deep purple, fluffy solid (Pa2.5R). This solid was then quaternised as 
previously described (33) to produce RBITC-labeled quaternised PAA-palmitoyl graft 
2.5% (QPa2.5R).  
 
 
 
2.3. Cell culture 
Caco-2 cells were cultured in EMEM (supplemented with 10 % foetal bovine serum, 1 % 
non-essential amino acids and 1% L-glutamine) at 5 % CO2, 95 % humidity and 37 C. 
All testing was carried out on cells of passage 45-60 (29).  
 
2.3.1. Polymer, insulin and complex Caco-2 uptake study 
Cells were seeded in 24 well polyester plates (Corning, UK) at 0.1x10
6
 cellsmL
-1
. Cells 
were grown over 3 days before testing. Polymer and insulin stock solution were prepared 
separately in a mixture of 0.01 M HCl:0.1 M Tris base (87:13 % (v/v)) (29) and then 
diluted in EMEM (supplemented with 1 % (v/v) non-essential amino acids and 1 % (v/v) 
L-glutamine). Pa2.5R solutions were prepared at 6 or 12 µgml
-1
, while QPa2.5R solutions 
were prepared at 48 or 96 µgml
-1
. The polymer concentrations were prepared in 
accordance to the IC50 study conducted previously on Caco2 cells using an MTT assay 
(Thompson et al., 2009).  QPa2.5R was also prepared at 6 µgmL
-1
 for comparison with 
Pa2.5R. FITC-insulin was prepared at either 3 or 6 ugml
-1
, while non-tagged insulin was 
prepared at 3 µgml
-1
. Selected polymer and FITC-insulin solutions were also prepared in 
calcium-free EMEM. Polymer and FITC-insulin solutions were mixed together with 
gentle agitation to produce polyelectrolyte -insulin complexes (PEC) with 
polymer:insulin concentrations of 6:3 (Pa2.5R) or 48:3 (QPa2.5R) µgml
-1
. EMEM was 
then removed from each well and the wells were then washed once with EMEM 
(containing no serum) prior to the addition of polymer, FITC-insulin or polymer-insulin 
solutions (1 mL). Sample solutions were incubated with the cells for 0.5, 1 or 2 h at 5 % 
CO2, 95 % humidity and 37 C. Selected samples of cells were stained with DAPI (300 
nM for 5 mins) to indicate the relative position of the nuclei. This was followed by the 
addition of 4% trypan blue (TB) for one min to determine cell viability. Samples were 
then aspirated from each well and the wells were washed (x3) with (serum free) EMEM. 
The plate was then incubated under the same conditions as before for 0.5 h prior to 
imaging with a fluorescence microscope (Leica DMI4000B, Leica Microsystems Ltd., 
UK). Each experiment was carried out in triplicate. 
 
2.3.2. Determination of PEC uptake mechanism 
Cells were grown and polymer, insulin and PEC samples were prepared as above. 
However wells were pre-incubated with either EMEM (calcium free) or non-tagged 
insulin for 1 h prior to sample addition.  
To further elucidate the mechanism of PEC cell uptake, cells were preincubated with the 
metabolic inhibitor sodium azide (10 mM) or endocytosis inhibitors cytochalasin D (0.1 
mg/mL) or nocodazole (1 mg/mL) for 30 mins prior to the application of the polymer 
complex and throughout the uptake experiment. Sample solutions were incubated with 
the cells for 0.5, 1 or 2 h at 5 % CO2, 95 % humidity and 37 C. Samples were then 
aspirated from each well and the wells were washed (x3) with (serum free) EMEM. The 
plate was then incubated under the same conditions as before for 0.5 h prior to imaging 
with the Leica DMI4000B fluorescence microscope. Each experiment was carried out in 
triplicate. 
  
2.3.3. Insulin transport study 
Caco-2 cells were seeded into 24 well polycarbonate transwell plates (Corning, UK) at a 
density of 3.9x10
4
 cellscm
-2
 and grown for 21 days in order to form a confluent 
monolayer.  The conditions used are as described in 2.3 except the media was 
supplemented with 2 % penicillin/streptomycin (+ 10000 UmL
-1/+ 10000 μLmL-1). Fresh 
media was added to the apical compartment of each well on days 3, 6 and 9 and the 
media was changed in both apical and basal compartments on days 12, 15, 18 and 20 
after seeding. 
TEER measurements were taken using a Millicell-ERS potentiometer with chop-stick 
electrodes (Millipore, USA) before and after media addition to monitor monolayer 
integrity. The transport study was carried out when all wells had a resistance within the 
range of 300-500 Ω.cm2. 
The transport study was conducted by addition of polymer and complex solutions applied 
to apical compartments after 0.5 h pre-incubation with HBSS alone. Polymer and 
complex solutions were made as in 2.3.1., except that stock solutions were diluted in 
HBSS instead of EMEM. After polymer and complex solutions were added to apical 
compartments the plate was incubated for 2 h at 5 % CO2, 95 % humidity and 37 C. 
Solutions were then aspirated and wells were washed with HBSS (x3) before placing the 
plate back in the incubator in EMEM for a further 2 h.  
Samples of media were collected from the basal compartment of each transwell plate and 
replaced with fresh HBSS at 0.5, 1, 1.5 and 2 h. The insulin concentrations of these 
samples were determined using a Mercodia bovine insulin ELISA kit (Diagenics Ltd, 
UK) and the final values presented have been adjusted to reflect the change in volume at 
each successive sampling point. TEER measurements were taken at 0 h (before sample 
addition) and at 0.5, 1, 1.5 and 2 h (before samples were removed) and at 3 and 4 h (after 
sample aspiration and plate washing). After the final TEER measurement, HBSS was 
removed from all wells and 0.1 mL of a 2.5 % (v/v) gluteraldehyde in PBS solution was 
added to each apical compartment. The plate was stored overnight in a refrigerator prior 
to further testing. Each experiment was carried out in triplicate.  Results of the TEER and 
the ELISA were then analysed using a one-tailed Student’s t test and presented as 
followed; p<0.05 *; <0.01** or p<0.001***. 
 
2.3.4. Transmission electron microscopy (TEM) 
Cell monolayers, were stored overnight in gluteraldehyde (2.5 % (v/v) in pH 7.4 
phosphate buffer) and then prepared for TEM analysis. Samples were treated with buffer 
for 45 mins, osmium oxide for 1 h and then washed with distilled water three times over 
30 mins. Samples were then exposed to ethanol solutions of 30-100 % (v/v) over 5.5 h. 
Membranes were then treated with ethanol:Spurr’s resin mixtures of 7:1 to 1:6 ratios over 
21 h. Membranes were then sliced in half and embedded in Spurr’s resin in a flat 
polythene embedding capsule. Cross-sections of the membranes (80-100 nm) were then 
obtained on a Leica UC6 and collected on 200 mesh grids. Cross-sections were stained 
for contrast using the Leica AC20.  The grids were viewed under a Philip’s CM10 
Transmission Electron Microscope. 
 
 
 
 
3. Results 
 
3.1. Caco-2 uptake of polymers and polymer-insulin nanocomplexes 
Caco-2 cells were treated with rhodamine labeled polymers, free FITC-insulin and 
rhodamine labeled polymer-FITC insulin nanocomplexes over 0.5-2 h periods. The IC50 
concentrations of Pa and QPa based on MTT assay were 0.021 and 0.114 mgmL
-1
, 
respectively (29) and hence Pa at 6 µgmL
-1
 and QPa at 48 µgmL
-1
 were used, which are 
non-cytotoxic at these concentrations (IC50). Insulin concentration was fixed at 3 µgmL
-1
.  
The microscopy images showed that free FITC-insulin was found in the cytoplasm within 
30 mins (Figure 1A). (These images are representative of each sample.) In contrast 
polymer and PEC uptake was slower and localisation within cells varied with polymer 
architecture. Pa was found localized in the cell membrane (after 2 h), while QPa was 
present in the cytoplasm/perinuclear region after 1 h (Figure 1B and C). Similar results 
were observed for Pa and QPa-insulin complexes. Figures 1D and 1E indicate that when 
insulin was complexed with Pa, it was only present around the cell membrane (after 2 h) 
while insulin was co-localised with QPa in the cell cytoplasm (after 1 h). Figure 1F 
confirms the co-localisation of QPa-insulin in the perinuclear area using a DAPI nuclear 
stain.   
The cells were also post-treated with trypan blue (TB) after the experiment to check for 
the integrity of the cell membrane (2). Non-viable cells or cells with damaged cell 
membranes were stained blue/black due to the diffusion of TB into these non-viable cells. 
As can be seen in bright field image of figure 2A, there was minimal staining present and 
the lack of staining of cells within the monolayer indicated the viability of the monolayer 
after treatment with PEC.  
In addition it was found that QPa PEC were located in cell cytoplasm after an hour even 
at a QPa:FITC insulin concentration of 6:3 µgmL
-1
 (Figure 2B). Therefore it appeared 
that the difference in QPa and Pa PEC uptake was not concentration dependent. 
 
3.1.1. Uptake mechanism of polymers and PEC into Caco-2 cells 
The uptake mechanisms were subsequently elucidated to check if calcium dependant 
processes or insulin receptor mediated uptake were involved. Pretreatment with a high 
concentration of insulin (3 µgmL
-1
) will result in the down regulation/blocking of insulin 
receptors. As expected, no free insulin uptake was observed following insulin pre-
treatment confirming the uptake of free insulin is likely to be mediated by insulin 
receptors (data not shown). However neither the absence of calcium nor down regulation 
of insulin receptors had any noticeable effect on QPa PEC uptake, while Pa PEC uptake 
was prevented in the absence of calcium in the media (Figure 3).  
It would appear that Pa PEC uptake required the presence of calcium ions in solution, 
while QPa PEC uptake involved some other mechanism(s). Therefore further studies 
involving the use of inhibitors of specific cellular processes were carried out on QPa-
insulin nanocomplexes Sodium azide (metabolic inhibitor) or cytochalasin D and 
nocodazole (inhibitors of the endocytotic trafficking pathway (34)) were used separately 
to block intracellular trafficking prior to QPa PEC addition (2). Cells were exposed to the 
respective inhibitors for 0.5 h prior to PEC addition. All PEC samples were also spiked 
with the inhibitors to maintain inhibition over the 1 h exposure to QPa-insulin samples. 
QPa was still taken up by cells even after blockage of endocytosis by nocodazole and 
cytochalasin D (Figure 4A and 4B).  
Endocytosis requires the presence of calcium (35) and QPa PEC demonstrated uptake 
despite the absence of calcium in the media. Together with the result showing that QPa 
PEC uptake was unaffected by endocytosis inhibitors, this indicates that perhaps these 
nano-complexes were taken up by an active process, which is demonstrated by figure 4C. 
The intensity of fluorescent emission of QPa-PEC in the cells appears weaker after 
treatment with sodium azide compared to normal conditions (Figure 1E). This would 
suggest a reduced degree of uptake when cellular energy dependent processes are 
blocked. Further work is required to quantify this change. 
 
3.2. Transport of insulin across Caco-2 monolayers 
The ability of these two amphiphilic polyelectrolytes (Pa and QPa) to facilitate 
paracellular transport of insulin across a cell monolayer was investigated. Caco-2 cells 
were grown in transwell plates over 21 days and then treated with: Pa (6 µgmL
-1
), QPa 
(48 µgmL
-1
), insulin (3 µgmL
-1
) or polymer-insulin complexes (6:3 or 48:3 µgmL
-1
 
respectively for Pa and QPa PEC). The TEER was measured at various time points over 4 
h after sample addition to the cells. TEER is a measure of cell junction integrity and will 
fall if the junctions are opened or damaged (6). The samples were removed after 2 h to 
check if the effect of opening tight junctions is reversible. This is important as it signifies 
that the polymers did not cause permanent damage to the tight junctions. Our result 
indicates that both polymers were able to open Caco-2 cell tight junctions after 30 mins 
(Figure 5). 
The TEER values dropped by around 15-35 % in the first 30 mins after polymer or PEC 
addition and then gradually climbed back up. After 1h, all samples containing either QPa 
or Pa, with or without the insulin (QPa p<0.001; QPaI p<0.05; Pa p<0.05; PaI p<0.01) 
showed a significant decrease in the TEER value suggesting that the presence of the 
polymer had facilitated the opening of junctions.  After sample removal at 2 h the TEER 
values for all monolayers returned to around 90 % of their original value demonstrating 
that this was a reversible process, Neither the control sample nor insulin alone displayed 
a discernable drop in TEER at any time point. This shows that insulin alone is unable to 
open tight junctions and that the fall in TEER was not due to a physical effect on 
addition/removal of samples/buffer.  
It was evident that the extent of TEER reduction is less for corresponding polymer-
insulin PEC. After 0.5 h, Pa PEC had lowered TEER by around 15 %, while Pa alone 
caused 30 % TEER reduction. Similarly QPa PEC lowered TEER by around 25 %, while 
QPa alone lowered TEER by 35 % after 0.5 h. It would appear that the presence of 
insulin reduced the interaction between the polymers and the tight junctions and hence 
resulting smaller reduction in TEER.  
The transport of insulin across Caco-2 cells was increased when complexed with Pa or 
QPa (Figure 6). Insulin concentration was greater for QPa PEC than Pa PEC, which 
corresponded well with the TEER values. QPa PEC produced a cumulative insulin 
concentration of 0.27 ngmL
-1
 in the basal compartment of plates, while Pa complexes 
only reached 0.14 ngmL
-1
 after 120 mins incubation, which is 52 % less compared to QPa 
PEC. After 30 minutes the effect of the complexation of the insulin with either Pa or QPa 
was significant (p<0.001 ***) while samples taken from 60 minute showed evidence of 
insulin in the lower chamber of the non-complexed insulin.  Transverse cross sections of 
the cells were also analysed using TEM to determine any differences in cell morphology 
after treatment with the polymer samples (Figure 7).  
Following the addition of the polymers the monolayers appeared intact and the microvilli 
were still present following the addition of the polymers demonstrating that the polymer 
did not damage the cells. It would have been expected that if the polymers are cytotoxic 
then the microvilli would have been destroyed (36). This figure is representative for all 
polymer and complex samples. 
 
4. Discussion 
In this study we have demonstrated that cellular uptake of free insulin is dependant on 
insulin-receptor interaction while insulin complexed with PAA amphiphilic 
polyelectrolytes uptake and transport are affected by the polymer architecture. Changes in 
polymer structure resulted in differences in cellular uptake rate, localisation within cells 
and mechanism of uptake as well as facilitation of insulin transport across cell layers. 
Free insulin was taken up via insulin receptors within 30 min while QPa and Pa PEC 
uptake took 1 h and 2 h respectively. Fluorescent microscopy images indicated co-
localisation of Pa-insulin PEC around cell membranes and the use of DAPI stain 
indicated a co-localisation of QPa-insulin PEC around the cell nuclei. This co-localisation 
suggests PEC were taken up as a whole and PEC did not dissociate into free insulin and 
AP before being taken up by the cells.  
To rule out the uptake mechanisms between Pa and QPa PEC was not due to the 
difference in polymer concentration, a lower concentration similar to Pa PEC was used. 
Given that QPa PEC uptake was still evident at low polymer concentrations (Figure 3B), 
it indicates that the differences in cellular localization and uptake mechanism was is 
likely to be due to the presence of quaternary ammonium moieties in QPa. Quaternary 
ammonium moiety confers a permanent, pH independent, positive charge which allows 
stronger electrostatic interaction with insulin (29). There are organic cationic transporters 
in the small intestine wall and Caco-2 cells which are used to mediate uptake of both 
endogenous cations, e.g. thiamine, cationic small drug molecules, e.g pancuronium 
bromide, and ‘model’ compounds, e.g. tetraethyl ammonium all of which have 
quaternary ammonium moieties (37). Therefore QPa may be able to interact with these 
transporters as well to facilitate its uptake into cells. However the cations taken up by 
these receptors are much smaller in molecular weight than QPa; all of them have a 
molecular weight of less than 800 Da (37) compared to QPa which has a molecular 
weight of around 15000 Da (33). Therefore further work involving saturating these 
receptors with known ligands would be required to demonstrate that such a large 
molecule could be taken up by these receptors.  
Depletion of intracellular stores of ATP using sodium azide appeared to reduce, but did 
not prevent, QPa PEC uptake. This was not due to cell death or damage as illustrated by 
the lack of trypan blue uptake.  This would suggest that QPa PEC uptake was partly 
energy dependent (2). Neither the use of cytochalasin D nor nocodazole, as inhibitors of 
the endocytotic trafficking pathway appeared to have any effect on QPa PEC uptake. It is 
possible that the uptake of QPa may be similar to that of another polycation, poly-L-
lysine. It was found that internalisation of poly-L-lysine was reduced when cell energy 
was depleted (26). However this is in contrast to Mao and coworkers who found that 
uptake of polyethylene glycol (PEG) grafted TMC was reduced in the presence of sodium 
azide as well as nocodazole and cytochalasin D, which they hypothesized the uptake was 
due to adsorptive endocytosis. The difference in the mechanism of uptake may be due to 
the absence of hydrophobic pendant groups in PEG grafted TMC. It is likely that 
hydrophobic groups may interact with cell membranes, but this has not yet been 
explored. 
The differences in polymer structure were also found to alter the extent of insulin 
transport across Caco-2 monolayers in transwell plates. QPa PEC resulted in a 50% 
increase of insulin concentration in the basal chambers compared to Pa PEC (Figure 6). 
This would again correlate well with cell uptake studies demonstrating the presence of 
quaternary ammonium moieties had an effect on PEC cell interaction. Free insulin was 
also present in the basal compartments although it was markedly lower in concentration 
compared to when the insulin was complexed with both Pa and QPa (Figure 6). Free 
insulin cannot passively diffuse across epithelial cells as it is a large (5800 D) molecule 
with a low lipophilicity (16). Since free insulin did not reduce TEER, it indicates that 
insulin itself is able to cross cells possibly via insulin receptors, as shown in our cellular 
uptake study. It is likely that insulin receptors in the GIT wall and in Caco-2 cells initiate 
receptor-mediated endocytosis (active transcellular transport) (16) where insulin can then 
be carried from apical to basal membranes via the Golgi-apparatus (16, 38). It might have 
been expected that any insulin entering cells would have been degraded by intracellular 
proteases (16, 39). However the relatively large concentration of insulin used (3 μgmL-1) 
could have resulted in enzyme saturation resulting in a small amount of insulin passing 
through the cells undegraded. Further work on intracellular enzymes and the rate and 
mechanisms of transcellular and exocytosis of insulin would be required to clarify this.  
The increase in insulin transport across Caco-2 monolayers on complexation with both Pa 
and QPa would indicate that AP were able to facilitate paracellular transport via tight cell 
junction opening. It was evident from the data that the presence of either Pa or QPa 
facilitated transport of insulin across the epithelial barrier after 30 minutes.  While non-
complexed insulin transport was only apparent after 60 minutes suggesting a difference in 
transport mechanism utilized.  This is similar to other polycations including poly-L-lysine 
and chitosan (19, 23-26). They are able to reversibly open tight cell junctions due to 
electrostatic interaction with F-actin and tight junctional proteins (ZO1 and occludin). 
During these interactions, changes in the F-actin cytoskeleton and cell localisation of 
ZO1 and occludin alter cell morphology and thus allow the opening of the junctions (19, 
23-26).  
However the APs ability to lower TEER appeared to be reduced by the formation of PEC. 
Reductions in TEER values were 10-15 % lower after 30 mins when PEC were incubated 
with Caco-2 cells compared to AP alone. It has been shown previously that the charge on 
the quaternised AP is roughly halved when they form PEC with insulin (29). A similar 
effect has been found with chitosan and heparin (15) and TMC with insulin (8). In both 
cases the zeta potential and subsequent ability to open tight cell junctions and facilitate 
transport across Caco-2 monolayers was reduced in comparison to solutions of polymer 
co-incubated with the protein. The formation of PEC is driven by Coulombic interactions 
between the positively charged moieties on the polymer and the negatively charged 
groups on the protein. Therefore charge reduction on the polymer chains will take place 
upon PEC formation resulting in a reduced ability to form electrostatic interactions with 
cell junction proteins (8). 
The relatively low concentration of insulin (1% of total insulin concentration) present in 
basal chambers for QPa PEC could be due to either insulin still remained in the apical 
chamber and/or the inherent limitations of paracellular protein transport (20) or 
incomplete transcellular transport (7, 8) It has been shown that paracellular transport is 
limited by the molecular weight of proteins and peptides due to the narrow size of 
junctions (2, 20). Kotzé et al. (1997b) found that the ability of TMC solutions (2.5 % 
(w/v)) to facilitate hydrophilic molecule transport across a Caco-2 monolayer was limited 
by the molecular weight of the molecule (20). The transport of [
14
C]-mannitol (182.2 D) 
was greater than that of buserelin (1299.5 D) which in turn was greater than dextran 
(4400 D); 12 %, 2.25 % and less than 1 % of the total dose in basal compartment of 
transwell plate after 180 mins, respectively. This occurred even though the TMC solution 
reduced TEER by around 80 % of its initial value within the first 20 min and the 
reduction was maintained up till 120 mins. Their work demonstrates clearly that 
facilitation of paracellular transport is largely dependent on the molecular weight of the 
hydrophilic molecule regardless of the extent of TEER reduction. Insulin has a larger 
molecular weight (5800 Da) compared to those model compounds and hence it is 
expected that its ability to go through tight junctions will be extremely limited.  
It has been shown that when formulated as part of a PEC, polyelectrolytes may be able to 
facilitate both paracellular and transcellular transport of proteins (7, 8). When formulated 
as PEC, polyelectrolytes have been shown to interact electrostatically with cell membrane 
and taken up by non-specific endocytosis/transcytosis as long as they have a positive 
charge and are less than 200 nm (7). This correlates well with our result since QPa and Pa 
PEC have an overall positive charge of between 23 to 58 mV with particle size of 118-
123 nm (29). As discussed above, Pa and QPa PEC were shown to be taken up by cells 
within 2 h and 1 h, respectively (Figure 1). Therefore facilitation of cellular uptake of 
PEC may have occurred within a similar time frame to tight junction opening. The slower 
uptake of PEC compared to free insulin may indicate some insulin was indeed trapped 
within cells during the transwell experimental work which could in part account for the 
low insulin concentrations in basal compartments. This slow uptake could mean that PEC 
may not have passed across monolayers transcellularly within the 2 h of the study and 
could have become trapped inside the Caco-2 cells in their Golgi apparatus or 
endoplasmic reticulum (18). In addition, it is not known if the dissociation of insulin from 
PEC occurs during the intracellular trafficking. Future studies involving tracking the 
dissociated insulin and analysis of intracellular insulin concentration will be required to 
confirm these hypotheses.  
 
5. Conclusion 
Our work is the first attempt to elucidate the cellular uptake mechanisms of amphiphilic 
polyelectrolyte- insulin complexes based on polyallylamine modified with hydrophobic 
and hydrophilic moieties. We have shown that Pa- and QPa-insulin PEC are taken up by 
Caco-2 cells via different mechanisms to free insulin. Insulin alone is taken up by insulin 
receptors and enters cell cytoplasm within 30 mins. Pa PEC are located around cell 
membranes after 2 h while QPa complexes are taken up into the cell after 1 h. Pa PEC 
appears to be taken up by a calcium dependent process while QPa PEC seems to be taken 
up by an active process(es). Both Pa and QPa are able to facilitate insulin transport across 
a Caco-2 cell monolayer by reversibly opening tight cell junctions (paracellular transport) 
as well as possibly promoting insulin transport through cells (transcellular transport).  
This work shows the potential of these PECs in oral protein delivery and future work 
using an in vivo model will be needed to determine the potential use of these novel 
polymers in promoting oral absorption of insulin. 
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Notations 
Q – quaternary ammonium moiety 
AP – amphiphilic polyelectrolyte 
Pa – palmitoyl 
PEC – polyelectrolyte complex 
TEER – transepithelial electrical resistance 
PAA – polyallylamine 
EMEM – eagle minimum essential media 
TB – trypan blue 
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Legends to Figures 
 
Figure 1. Fluorescent microscopy images of Caco-2 cells (representative of each sample) 
after incubation with different samples at 37 
o
C.  (A) FITC-insulin after 30 min 
incubation (3 µgml
-1
); (B) Pa after 2 h (6 µgml
-1
); (C) QPa after 1 h (48 µgml
-1
); (D) Pa 
PEC after 2 h (polymer:insulin of 6:3 µgml
-1
); (E) QPa PEC after 1 h (polymer:insulin of 
48:3 µgml
-1
); (F) QPa PEC (polymer:insulin of 48:3 µgml
-1
) post-treated with DAPI stain 
(Mag. x400 (to eyepiece)).  
 
Figure 2. Microscopy images of incubation of Caco-2 cells with polymer-insulin PEC for 
1 h at 37 
o
C. Exposure of Caco-2 cells to (A) bright field of QPa-insulin complex 
(polymer:insulin of 48:3 µgml
-1
) post-treated with trypan blue (representative of all PEC 
samples); (B) fluorescent image of QPa-insulin complex (polymer:insulin of 6:3 µgml
-1
) 
(scale bar 50m). 
 
Figure 3. Fluorescent microscopy images of incubation of Caco-2 cells with polymer-
insulin PEC at 37 
o
C. Cells pre-treated with calcium-free media for 1 h then exposed to 
Pa-insulin for 2 h (A) or QPa PEC  for 1 h (B); Cells pre-treated with 3 µgmL
-1
 insulin 
for 1 h then exposed to Pa PEC for 2 h (C) or QPa PEC for 1 h (D) (scale bar 50m). 
 
Figure 4. Fluorescent microscopy images of incubation of Caco-2 cells with QPa-insulin 
PEC for 1 h at 37 
o
C. Cells exposed to QPa-insulin for 1 h after pre-treatment with (A) 
nocodazole; (B) cytochalasin D; (C) sodium azide for 0.5 h prior to QPa-insulin exposure 
(scale bar 50m). 
 
Figure 5. TEER of Caco-2 cells exposed to: HBSS buffer; Insulin (3 µgmL
-1
); Pa (6 
µgmL
-1
); QPa (48 µgmL
-1
); Pa:Insulin (6:3 µgmL
-1
) or QPa:Insulin (48:3 µgmL
-1
) for 2 
h. Samples were removed at 2h, cells washed (x3) and replaced with fresh media (n=3; ± 
SD).  After 1h, all samples containing either Qpa or Pa with and without insulin showed 
significant decrease in the TEER value when compared to control.  Insulin alone showed 
no significant decrease. 
 
 
 
Figure 6. Cumulative insulin concentration in the basal compartment of transwell plates 
after addition of: Insulin (3 µgmL
-1
); Pa-Insulin (6:3 µgmL
-1
) or QPa-Insulin (48:3 
µgmL
-1
) to apical compartments (n=3; ± SE).  (*<0.05; **<0.01; ***<0.001 effect of 
polymer when compared with insulin alone at respective time point). Insulin values at 30 
minutes were below assay detection limits. 
 
Figure 7. TEM cross sections of Caco-2 cells after exposure to: (A) Pa (6 µgmL
-1
); (B) 
Pa-Insulin (6:3 µgmL
-1
) for 2 h. Scale bar = 2 µm. 
 
